SteadyMed raised $2 million in funding round led by Samson Venture Partners January 29, 2009
Posted by israelhealthcare in Uncategorized.Tags: Drug Delivery
add a comment
Medical device startup SteadyMed closed a $2 million round of funding led by Samson Venture Partners, the investment management arm of Becker & Associates Consulting, an FDA consulting firm in Washington, DC specializing in innovative medical devices and drugs. Prior investors in SteadyMed include the RAD Biomed Incubator, and its Chairman, Yehuda Zisapel.
SteadyMed, founded in 2005, develops sophisticated miniature disposable infusion pumps with unique drug delivery characteristics that provide enhanced portability and optimized infusion algorithms for large molecules and high-viscosity drugs. The Company is targeting interest from several major pharma companies having biological drugs requiring the specialized drug-delivery characteristics enabled by the PatchPump technology.
“The SteadyMed drug delivery platform has the potential to expand the market for currently approved drugs, and, perhaps most importantly, create markets that do not yet exist for new molecular entities, especially certain biologics,” said Karen M. Becker, CEO of Becker & Associates Consulting and Chair of the Samson Investment Committee.
Based in Tel Aviv, Israel, SteadyMed is developing innovative devices for delivering injectable therapeutic drugs for chronic conditions. The company is managed by Yossi Aldar, who was previously the Managing Director of Versamed Medical Systems and before that the CEO and co-founder of Flight Medical.
Sponsored Links – Brain Fitness for Adults | Dynamic Single Cell Monitoring
Rikaken to distribute Cell Kinetics’ fluorescence imaging systems in Japan April 8, 2008
Posted by israelhealthcare in Medical Research.Tags: fluorescence imaging, single cell research, single living cells
add a comment
Cell Kinetics, a provider of platform technology that enables fluorescence-based imaging of thousands of individual living cells, has signed an exclusive distribution agreement with Rikaken, a leading Japanese distributor of medical laboratory equipment and chemicals operating, for the marketing and distribution of Cell Kinetics’ CKChip system in Japan.
“This distribution agreement with Rikaken reflects the first step in our commercialization plans to enter into strategic distribution agreements for our CKChip with first class partners in key markets such as Japan, Europe and of course the US,” said Dr. Asaf Ben-Arye, Cell Kinetics’ President and CEO.
“The CKChip is a unique new technology for single cell research, in particular for acquisition of kinetic data, and we believe that the CKChip has various research and, ultimately, clinical applications,” said Yoshio Morikawa, The President of Rikaken. ”This contract with Cell Kinetics adds an important dimension to our management strategy, and we are very excited to be able to provide this new product offering to our established customer base, as well as see this as allowing us to expand that base even further.”
Cell Kinetics, an indirect majority-owned subsidiary of Medis Technologies, is developing and will market a series of products, based on its Cell Carrier technology. The CKChip can accommodate up to 10,000 cells on individual wells for measuring reactions of living cells in a static state over time, using simple imaging methods such as fluorescence microscopy.
Rikaken is responsible for the distribution of general chemicals and reagents, lab disposables, clinical test equipment, lab instruments, and clinical test equipment in Japan.
Sponsored Links – Brain Training Games | Healthy living Food
Aerotel partner with Turkcell to market wireless telemedicine solutions in Turkey October 1, 2007
Posted by israelhealthcare in Telemedicine.Tags: Aerotel Medical Systems, eHealth and telemedicine, home care, SKeeper personal safety phone, Turkcell, Wireless ECG
add a comment
Telemedicine and remote monitoring solutions provider Aerotel Medical Systems partner with Turkish mobile operator Turkcell to market Aerotel’s Advanced Wireless Telemedicine and Telecare Solutions in Turkey. The two companies will demonstrate Aerotel’s solutions at CeBIT Eurasia, held in Istanbul, Turkey, 2-7 October, 2007.
“By offering innovative mobile and wireless monitoring solutions we are enabling people on the move to get all the benefits of telemedicine and telecare technologies, enjoy their lives and save costs,” explains David Rubin, Aerotel’s CEO. “Aerotel’s mobile solutions offer significant clinical and economical benefits for patients, families, physicians and administrators.”
At CeBIT Eurasia the two companies will be demonstrating Wireless homecare hubs for connecting multiple medical sensors in the home; Wireless ECG and SKeeper personal safety phone, a wearable emergency alarm and cellular communicator device developed by Aerotel.
Turkcell is the leading GSM operator in Turkey with 33.8 million postpaid and prepaid customers. Aerotel Medical Systems is leading provider of medical diagnostic systems and devices for home care, eHealth and telemedicine.
Sponsored Links – Brain Games for Adults | Dynamic Single Cell Analysis
Medical diagnostic applications developer Pocared Diagnostics raised $10.7 million June 13, 2007
Posted by israelhealthcare in Medical Diagnostic.add a comment
Medical diagnostic applications developer Pocared Diagnostics raised $10.7 million in a financial round of led by Elron and SCP Vitalife Partners.
“We view Pocared as a highly innovative company presenting an out-of-the-box solution and introducing a disruptive platform technology in the field of real-time IVD,” said Elad Frenkel, Elron’s Director of Business Development.
Pocared provides an innovative solution for real-time, reagentless In-Vitro Diagnostics (IVD). The company wide technological platform may be used to address a wide range of medical and industrial diagnostic applications.
Pocared’s Point-of-Care (POC) diagnostic systems, based upon selective spectrum technology, enable immediate, on-site analysis of human fluids and specimen in order to provide physicians with real-time detection, identification and antibiotic sensitivity of pathogenic bacteria.
Sponsored Links – Single Cell Tracking | Healthy Balanced Diet
Israel’s life science industry exports will doable to $10 billion by 2009 June 6, 2007
Posted by israelhealthcare in Life Science.add a comment
Exports of the Israel’s life science industry will doable to $10 billion by 2009, according to a new forecast by Israel Export Institute, that revealed before the opening of Biomed 2007 conference, the key event of Israel’s life science industry.
The sector’s exports increased by 32% to $4.7 billion in 2006 and grow by 26% to $1.2 billion in the first quarter of 2007.
Other new figures that reported towards the Biomed Israel 2007 Week, show that in the last six months (November 2006 to May 2007), the Israel Chief Scientist office earmarked $100 million in budgets for the life science industry.
The Chief Scientist handled applications from 58 companies for support in 114 specific projects. Of the $100 million given to the life science industry, research and development budgets accounted for $41 million.
The figures also show that support of the life science industry continues to grow its share of the Chief Scientist’s “budget pie”. In 2000, the Chief Scientist office allocated 14% of its budget to this area. By 2003, the rate was 23% and in 2006 28% of the total budget.
A breakdown into industry segments shows that biotechnology received the largest share of the Chief Scientist’s R&D allocations with $31 million, compared with $27 million in 2005. Medical devices protected its share at $25 million, while pharmaceuticals increased their share of R&D support from $17 million in 2005 to $22 million in 2006.
Total R&D grants extended by the Chief Scientist office for life science ventures in 2006 was $78 million. 20% of the approved programs were for medical devices, 43% for bio-pharma and 37% for biotechnology.
Sponsored Links – Healthy Eating Food | Live Cell Fluorescence Imaging
Biolert and Brainsway won the UK Medical Futures Innovation Awards of 2007 June 3, 2007
Posted by israelhealthcare in Neuroscience.add a comment
Israeli medical device startups, Biolert and Brainsway, have won the Medical Futures Innovation Awards of 2007 in the category of Mental Health & Neuroscience. The Medical Futures Innovation Award is the United Kingdom’s most sought after healthcare award, supported by the UK prime minister.
Biolert have been selected as an Award winner in the category of ‘Neuroscience Innovation’ for its innovation solution EpiLert, a wireless device alerting caregivers of an on-going epileptic attack. It was chosen on three principle criteria, namely; novelty; impact on patient care and its viability, whether that be clinical, technical or commercial.
Brainsway has won the award for its unique Deep TMS technology, aimed for the non-invasive treatment of various neurological and psychiatric disorders.
The award is aimed to encourage, support and reward clinical and commercial excellence from the healthcare & life sciences professions. The criteria for the award emphasize the potential benefit for patients, the novelty and the technical and commercial applicability. Awards will be officially granted on June 14 at the Innovators Gallery Exhibition & Awards Ceremony in London, UK.
BioLert, Brainsway and about 100 other projects entered the contest of the ‘mental health and neuroscience’ group. The judge committee, including leading professors of psychiatry, neurology and business people in the UK, based their judgment on the combination of contribution to medicine, innovation and financial promise.
Sponsored Links – Healthy Living Diet Food | Lymphedema Compression Garments
Israel Life Science M&As and IPOs totaled $736 million in 2006 May 17, 2007
Posted by israelhealthcare in Life Science.Tags: BioLineRX, Itamar Medical, life sciences
1 comment so far
The number of Mergers & Acquisitions (M&As) and IPOs of Israeli life sciences companies totaled $736 million in 2006. This amount accounts for 7.4% of total M&As carried out by Israeli technology companies in 2006. According to a new survey held by IVC Research Center towards the Biomed Israel 2007 Week.
Nine life science companies raised $85 million in IPOs carried out in stock exchanges in the USA, Europe, Asia and Israel, which accounts for 12.3% of the IPOs of all high tech companies in Israel. 41% of the IPOs of life science companies were of medical instrumentation companies. The survey also reveals that 77 new life science companies were established from the beginning of 2006.
“2007 figures testify for an increase in the scope of IPOs by life science companies as compared with 2006, said Efrat Zakai, IVC’s research manager. ”From the beginning of the year, companies issued shares at total value of $145 million. The three most prominent IPOs were of BioLineRX and Itamar Medical, which were issued at the Tel Aviv Stock Exchange, and Rosetta Genomics, which was issued at NASDAQ at $30.2 million.”
Sponsored Links – Medical Compression Device | Olive Oil Baby Skin Care
NovaThera and Gamida Cell collaborate to develop cell therapeutics for lung disease May 11, 2007
Posted by israelhealthcare in Cell Therapeutics.Tags: Lung disease, therapeutic treatments
1 comment so far
NovaThera and Gamida Cell signed a collaboration agreement aimed at developing cell therapeutic treatments for lung repair and regeneration. The two companies will pool technology and expertise and work together with the clinical team at Papworth Hospital in the UK towards advancing cell therapy approaches for treating lung disease.
NovaThera specializes in pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering to provide innovative therapeutic solutions.
Gamida Cell develops therapeutics using proprietary technologies that expand populations of hematopoietic stem/progenitor cells such as those derived from cord blood for the treatment of hematological diseases as well as for tissue regeneration applications.
“This is a very exciting development, and could be a huge step towards a practical approach to the regeneration and repair of lungs severely damaged by incurable diseases such as emphysema and smoking,” said Dame Professor Julia Polak, from the Imperial College London and a world expert in the field of lung pathology.
Lung disease is a major killer and the cause of chronic illness in the western world. Research indicates that considerable advances in treating lung disease could come from using stem cells to repair and regenerate damaged tissues.
Sponsored Links – Compression Therapy for Leg Ulcers | Natural Skin Care Products
Cancer treatment developer GammaCan raised $6.5 million March 6, 2007
Posted by israelhealthcare in Drug Discovery.Tags: cancer, immunotherapy, melanoma
add a comment
GammaCan, a developer of novel immunotherapies to treat cancer, raised $6.5 million in a private placement with a group of investors lead by T.R. Winston & Company.
“These funds will enable us to continue the development of VitiGam for the treatment of Stage III and Stage IV melanoma,” said Patrick Schnegelsberg, CEO.
GammaCan develops innovative immunotherapy and related approaches to treat cancer. GammaCan is planning to submit its Investigational New Drug Application (IND) for VitiGam to the FDA in the near future. The Company is expecting to commence human clinical trials shortly thereafter.
VitiGam is a first-in-class IgG-based anti-cancer immunotherapy being developed for the treatment of Stage III and Stage IV melanoma. VitiGam is an IgG-based product manufactured from the plasma of donors with Vitiligo, a benign skin condition affecting up to 2% of the general population.
Sponsored Links – Garlic Grinder | Sequential Compression Device | Derma Skin Care Ointments
Telemedicine systems provider Aerotel acquires wireless monitoring developer Tadiran LifeCare January 29, 2007
Posted by israelhealthcare in Monitoring System, Telemedicine.add a comment
Transtelephonic telemedicine systems provider Aerotel Medical Systems has closed the purchase of Tadiran LifeCare division activities from Tadiran Spectralink, a supplier of wireless communications solutions for critical missions.
Tadiran LifeCare is a developer of innovative wireless monitoring solutions for improving people’s health, safety and quality of life. Its products combine miniature biosensors with wireless technologies in order to provide peace of mind for users, their families and caregivers.
“By integrating new, cutting-edge wireless monitoring technologies into our systems we are expanding our offering in the area of wireless and mobile solutions,” explains David Rubin, Aerotel CEO. “Wireless technologies are becoming essential for next generation cost-effective and on-going monitoring. Tadiran LifeCare products will become part of Aerotel’s growing portfolio of wireless based remote monitoring solutions for homecare and telehealth.”
Sponsored Links – Olive Oil Healthy Food | Innovative Kitchen Aid | Lymphedema Compression Boots
